Vor Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vor Biopharma Inc. on July 9, 2025. The filing discloses the appointment of a new Chief Financial Officer and related compensatory arrangements. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
On July 9, 2025, the Board of Directors appointed Sandesh Mahatme as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective immediately. Mr. Mahatme brings extensive experience from National Resilience Inc., Sarepta Therapeutics, Celgene, and Pfizer.
Compensation and Employment Terms
- Base Salary: $480,000 annually.
- Annual Bonus: Discretionary, targeted at 40% of base salary.
- Signing Bonus: One-time payment of $274,000, subject to repayment under specific termination conditions within the first 12 months.
- Equity Grant: 13,882,750 restricted stock units (RSUs) under the 2023 Inducement Plan.
- Severance: 12 months of base salary and prorated bonus for termination without cause or for good reason; increases to 18 months of salary and 150% of target bonus in connection with a change in control, including accelerated equity vesting.
Risks and Contingencies
The filing notes that the signing bonus is subject to repayment if employment terminates under certain circumstances within the first twelve months. Severance benefits are contingent upon the execution of a release of claims and a post-employment non-competition agreement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as Exhibit 10.1 for complete terms and conditions.
- Confirm the impact of the 13,882,750 RSU grant on existing share count and dilution.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for the company's financial performance, as this 8-K contains no operational or financial data.